tumor heterogeneity

Research into how pancreatic tumors adapt to stress could lead to a new treatment approach.

Most differences in gene expression among cells within a tumor are likely due to environment or noise, a study suggests. 

Islands of rigid cells within a matrix of soft ones allow tumors to be both solid and fluid, granting them toughness without losing the ability to break apart.

At Brigham and Women’s Hospital, the cancer biologist is combining research into the tumor microenvironment with the principles of neuroscience to tease apart how cancers grow—and how to stop them.

Single cell and spatial assays provide information on different aspects of cancer.

A new study reports that human colon cancer cells at imminent risk of death can instead develop characteristics needed to colonize new parts of the body.

How stem cells in human teeth respond to different environmental conditions offers clues for regenerative medicine.

Single cell and spatial analyses of cell-based cancer therapeutics and patient responses enhance treatment efficacy.

When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker.

Strategies to trick, manipulate, and direct the evolution of tumors

New therapeutic approaches in oncology aim to manipulate or block cancer’s adaptation to treatment.

Hot topics in cancer research from the annual meeting of the American Association for Cancer Research

Cancer treatment becomes more and more personal.

Considering “targeted therapeutics” in the face of intra-patient heterogeneity. 

By scrutinizing gene expression profiles instead of individual oncogenes, Todd Golub launched a powerful platform for diagnosing, classifying, and treating cancer.

Advances in genomics and cancer biology will alter the design of human cancer studies.

Tumor cells can exhibit different behaviors despite being genetically indistinguishable.

While exploring the genetics of a rare type of tumor, Stephen Baylin discovered an epigenetic modification that occurs in most every cancer—a finding he’s helping bring to the clinic.